4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Liminatus Pharma, Inc. (LIMN) operates in the Biotechnology industry and is headquartered in Cerritos, United States with about 1 employees. Its market capitalization is roughly $8 million. In the fiscal year ended 2025-12-31, LIMN reported $0M in revenue and ($10M) in net income.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($3M) | ($3M) | ($5M) | ($3M) |
| Net Income | ($10M) | ($4M) | ($5M) | ($3M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | — | $0M | $0M |
| Operating Income (EBIT) | ($1M) | ($1M) | ($1M) | — | ($0M) | ($0M) |
| Net Income | ($1M) | ($8M) | ($2M) | — | ($0M) | ($0M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $0M | $5M | $2M | $7M |
| Total Liabilities | $10M | $25M | $18M | $18M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LIMN viewer.
About TickerBase · Data methodology & sources